Implementation of the vitiligo area scoring index in clinical studies of patients with vitiligo: a scoping review.
Clinical trials
Outcome measures
Vitiligo
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
03
02
2023
accepted:
14
03
2023
revised:
03
02
2023
medline:
29
8
2023
pubmed:
8
4
2023
entrez:
7
4
2023
Statut:
ppublish
Résumé
The vitiligo area scoring index (VASI) is a validated, reliable clinician-reported outcome measure widely used to assess the extent of skin depigmentation seen in patients with vitiligo and to measure patient responses to therapies for vitiligo in clinical trials. However, its implementation in studies is inconsistent and makes comparing results across different studies difficult. The aim of this scoping review is to summarize interventional clinical studies that applied the VASI to measure vitiligo and identify variability in VASI implementation. A systematic search of Ovid Medline, Embase, Web of Science, Cochrane, and ClinicalTrials.gov was performed. Interventional studies published between January 1946 and October 2020 that used the VASI as an outcome measure for assessing vitiligo response were reviewed for methodological approach. Great heterogeneity was found within the 55 included interventional studies that used VASI as an outcome measure. A total of 9 VASI subtypes were described by the authors within 10 intervention categories. VASI determined study eligibility in one study. Body surface area was most frequently established using inconsistent methods. We found unclear or ambiguously scaled assessments of depigmentation. Most VASI outcomes were reported as mean absolute difference, percentage VASI improvement, and percentage of patients who achieved the VASI endpoint. The VASI score was over 100 in one study. Our scoping review revealed many VASI methodology variations in interventional clinical studies of vitiligo. While VASI is a standard method to measure vitiligo changes, substantial heterogeneity in methodology limits reliable comparison and interpretation of findings from different clinical trials. Our findings may be used as a foundation to standardize the VASI outcome measure methodology, allowing for improved clinician training and rigorous data analysis across vitiligo research groups worldwide.
Identifiants
pubmed: 37029284
doi: 10.1007/s00403-023-02608-3
pii: 10.1007/s00403-023-02608-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2233-2259Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abd-Elazim NE, Yassa HA, Mahran AM (2020) Microdermabrasion and topical tacrolimus: a novel combination therapy of vitiligo. J Cosmet Dermatol 19(6):1447–1455. https://doi.org/10.1111/jocd.13193
doi: 10.1111/jocd.13193
pubmed: 31668003
Abdel-Naser MB, El-Khateeb EA, Sallam TH, Habib MA (2006) Endothelin-1 is significantly elevated in plasma of patients with vitiligo treated with psoralen plus ultraviolet a. Clin Exp Dermatol 31(4):571–575. https://doi.org/10.1111/j.1365-2230.2006.02148.x
doi: 10.1111/j.1365-2230.2006.02148.x
pubmed: 16716165
Abu Zeid O, Omar N, El Sharkawy D (2020) The efficacy of combining fractional co2 laser and tacrolimus ointment in the treatment of vitiligo. J Egypt Women’s Dermatol Soc 17(1):25–30. https://doi.org/10.4103/JEWD.JEWD_41_19
doi: 10.4103/JEWD.JEWD_41_19
Abu-Raghif AR, Ali NM, Farhood IG, Hameed MF, Sahib HB (2013) Evaluation of a standardized extract of ginkgo biloba in vitiligo remedy. Asian journal of pharmaceutical and clinical research 6(SUPPL.5):127‐130. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00910867/full
Anbar TS, Mohammed SS, Mohamed DM, Abdel-Rahman AT (2019) Clinical evaluation of interrupted versus continuous narrowband ultraviolet b phototherapy in nonsegmental vitiligo treatment: a prospective randomized comparative study. Dermatol Ther 32(6):e13117. https://doi.org/10.1111/dth.13117
doi: 10.1111/dth.13117
pubmed: 31606939
Awad S, Morsy H, Abdel-Aal A, Ibrahim A (2016) Effect of narrowband ultraviolet b phototherapy on serum vitamin d levels in patients with vitiligo. J Egypt Womenʼs Dermatol Soc 13:37–42. https://doi.org/10.1097/01.EWX.0000473579.35791.9a
doi: 10.1097/01.EWX.0000473579.35791.9a
Bae JM, Zubair R, Ju HJ et al (2021) Development and validation of the fingertip unit for assessing facial vitiligo area scoring index (f-vasi). J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2021.06.880
doi: 10.1016/j.jaad.2021.06.880
pubmed: 34246695
pmcid: 9105780
Bansal S, Sahoo B, Garg V (2013) Psoralen-narrowband uvb phototherapy for the treatment of vitiligo in comparison to narrowband uvb alone. Photodermatol Photoimmunol Photomed 29(6):311–317. https://doi.org/10.1111/phpp.12072
doi: 10.1111/phpp.12072
pubmed: 24118425
Bishnoi A, Vinay K, Kumaran MS, Parsad D (2020) Oral mycophenolate mofetil as a stabilizing treatment for progressive non-segmental vitiligo: results from a prospective, randomized, investigator-blinded pilot study. Arch Dermatol Res. https://doi.org/10.1007/s00403-020-02108-8
doi: 10.1007/s00403-020-02108-8
pubmed: 32737577
Cervelli V, De Angelis B, Balzani A, Colicchia G, Spallone D, Grimaldi M (2009) Treatment of stable vitiligo by recell system. Acta Dermatovenerol Croat 17(4):273–278
pubmed: 20021980
El-Zawahry BM, Bassiouny DA, Sobhi RM et al (2012) A comparative study on efficacy of uva1 vs. Narrow-band uvb phototherapy in the treatment of vitiligo. Photodermatol Photoimmunol Photomed 28(2):84–90. https://doi.org/10.1111/j.1600-0781.2011.00643.x
doi: 10.1111/j.1600-0781.2011.00643.x
pubmed: 22409711
El-Zawahry BM, Elmasry MF, Ragab A (2019) The role of long-wavelength ultraviolet al (uva1) in acral vitiligo. J Cosmet Dermatol 18(4):1155–1160. https://doi.org/10.1111/jocd.12808
doi: 10.1111/jocd.12808
pubmed: 30375144
El-Zawahry MB, Zaki NS, Wissa MY, Saleh MA (2017) Effect of combination of fractional co(2) laser and narrow-band ultraviolet b versus narrow-band ultraviolet b in the treatment of non-segmental vitiligo. Lasers Med Sci 32(9):1953–1958. https://doi.org/10.1007/s10103-017-2290-y
doi: 10.1007/s10103-017-2290-y
pubmed: 28748302
Emiroglu N, Cengiz F, Bahali A, Bıyık Ozkaya D, Su O, Onsun N (2018) Effectiveness of the capparis spinosa treatment in vitiligo. Bezmialem Sci 5:145–149. https://doi.org/10.14235/bs.2016.1007
doi: 10.14235/bs.2016.1007
Farag A, Hammam M, Al-Sharaky D, Hassan R, ElShafey E, Ali N (2019) Role of chemokine ligand 22 in narrow-band ultraviolet b-induced pigmentation in vitiligo: an immunohistochemical study. J Egypt Womenís Dermatol Soc 16(2):97–104. https://doi.org/10.4103/jewd.Jewd_4_19
doi: 10.4103/jewd.Jewd_4_19
Farag AGA, Hammam MA, Al-Sharaky DR, El-Boghdady GM (2019) Leucine-rich glioma inactivated 3: a novel keratinocyte-derived melanogenic cytokine in vitiligo patients. An Bras Dermatol 94(4):434–441. https://doi.org/10.1590/abd1806-4841.20198250
doi: 10.1590/abd1806-4841.20198250
pubmed: 31644616
pmcid: 7007044
Ghorbanibirgani A, Khalili A, Rokhafrooz D (2014) Comparing nigella sativa oil and fish oil in treatment of vitiligo. Iran Red Crescent Med J 16(6):e4515. https://doi.org/10.5812/ircmj.4515
doi: 10.5812/ircmj.4515
pubmed: 25068060
pmcid: 4102993
Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H (2004) Parametric modeling of narrowband uv-b phototherapy for vitiligo using a novel quantitative tool: the vitiligo area scoring index. Arch Dermatol 140(6):677–683. https://doi.org/10.1001/archderm.140.6.677
doi: 10.1001/archderm.140.6.677
pubmed: 15210457
Handjani F, Aghaei S, Moezzi I, Saki N (2017) Topical mycophenolate mofetil in the treatment of vitiligo: a pilot study. Dermatol Pract Concept 7(2):31–33. https://doi.org/10.5826/dpc.0702a06
doi: 10.5826/dpc.0702a06
pubmed: 28515990
pmcid: 5424659
Hegazy RA, Fawzy MM, Gawdat HI, Samir N, Rashed LA (2014) T helper 17 and tregs: a novel proposed mechanism for nb-uvb in vitiligo. Exp Dermatol 23(4):283–286. https://doi.org/10.1111/exd.12369
doi: 10.1111/exd.12369
pubmed: 24617827
Huggins RH, Henderson MD, Mulekar SV et al (2012) Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the united states. J Am Acad Dermatol 66(5):785–793. https://doi.org/10.1016/j.jaad.2011.05.002
doi: 10.1016/j.jaad.2011.05.002
pubmed: 21864935
Ibrahim H, El Taieb M, El Gamel Z, El Saied AR (2018) Effect of narrow-band ultraviolet b on the serum of 25-hydroxyvitamin d in vitiligo patients. J Cosmet Dermatol 17(5):911–916. https://doi.org/10.1111/jocd.12515
doi: 10.1111/jocd.12515
pubmed: 29524288
Iraji F, Banihashemi SH, Faghihi G, Shahmoradi Z, Tajmirriahi N, Jazi SB (2017) A comparison of betamethasone valerate 0.1% cream twice daily plus oral simvastatin versus betamethasone valerate 0.1% cream alone in the treatment of vitiligo patients. Adv Biomed Res 6:34. https://doi.org/10.4103/2277-9175.203159
doi: 10.4103/2277-9175.203159
pubmed: 28516068
pmcid: 5385703
Kalafi A, Jowkar F (2014) Evaluation of the efficacy of topical tetracycline in enhancing the effect of narrow band uvb against vitiligo: a double-blind, randomized, placebo-controlled clinical trial. ISRN Dermatol 2014:472546. https://doi.org/10.1155/2014/472546
doi: 10.1155/2014/472546
pubmed: 24665368
pmcid: 3934486
Khemis A, Fontas E, Moulin S, Montaudié H, Lacour JP, Passeron T (2020) Apremilast in combination with narrowband uvb in the treatment of vitiligo: A 52-week monocentric prospective randomized placebo-controlled study. J Invest Dermatol 140(8):1533-1537.e1532. https://doi.org/10.1016/j.jid.2019.11.031
doi: 10.1016/j.jid.2019.11.031
pubmed: 32004567
Kitchen H, Wyrwich KW, Carmichael C et al (2022) Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the vitiligo area scoring index (vasi). Dermatol Ther (Heidelb) 12(7):1623–1637. https://doi.org/10.1007/s13555-022-00752-8
doi: 10.1007/s13555-022-00752-8
pubmed: 35773559
pmcid: 9245872
Komen L, da Graça V, Wolkerstorfer A, de Rie MA, Terwee CB, van der Veen JP (2015) Vitiligo area scoring index and vitiligo european task force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. Br J Dermatol 172(2):437–443. https://doi.org/10.1111/bjd.13432
doi: 10.1111/bjd.13432
pubmed: 25278165
Lim HW, Grimes PE, Agbai O et al (2015) Afamelanotide and narrowband uv-b phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 151(1):42–50. https://doi.org/10.1001/jamadermatol.2014.1875
doi: 10.1001/jamadermatol.2014.1875
pubmed: 25230094
Liu B, Sun Y, Song J, Wu Z (2020) Home vs hospital narrowband uvb treatment by a hand-held unit for new-onset vitiligo: a pilot randomized controlled study. Photodermatol Photoimmunol Photomed 36(1):14–20. https://doi.org/10.1111/phpp.12495
doi: 10.1111/phpp.12495
pubmed: 31206787
Majid I (2010) Topical placental extract: does it increase the efficacy of narrowband uvb therapy in vitiligo? Indian J Dermatol Venereol Leprol 76(3):254–258. https://doi.org/10.4103/0378-6323.62964
doi: 10.4103/0378-6323.62964
pubmed: 20445295
Majid I (2010) Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet b therapy in vitiligo? A left-right comparison study. Photodermatol Photoimmunol Photomed 26(5):230–234. https://doi.org/10.1111/j.1600-0781.2010.00540.x
doi: 10.1111/j.1600-0781.2010.00540.x
pubmed: 20831696
Merhi R, Canu D, Barnetche T et al (2022) Assessment of vitiligo area scoring index (vasi), facial-vasi and vitiligo extent score using standardized photography of patients with vitiligo. Br J Dermatol 187(3):422–424. https://doi.org/10.1111/bjd.21246
doi: 10.1111/bjd.21246
pubmed: 35289925
Mou KH, Han D, Liu WL, Li P (2016) Combination therapy of orally administered glycyrrhizin and uvb improved active-stage generalized vitiligo. Braz J Med Biol Res. https://doi.org/10.1590/1414-431x20165354
doi: 10.1590/1414-431x20165354
pubmed: 27464024
pmcid: 4964896
Nada HR, El Sharkawy DA, Elmasry MF, Rashed LA, Mamdouh S (2018) Expression of janus kinase 1 in vitiligo & psoriasis before and after narrow band uvb: a case-control study. Arch Dermatol Res 310(1):39–46. https://doi.org/10.1007/s00403-017-1792-6
doi: 10.1007/s00403-017-1792-6
pubmed: 29127481
Nahidi Y, Pouran L, Tayyebi Meibodi N, Vakili V, Kardan G (2019) Serum level of vitamin d3 in vitiligo patients before and after treatment with narrow band uvb. Is there an association with treatment? Iran J Dermatol 22(1):1–6. https://doi.org/10.22034/ijd.2019.98364
doi: 10.22034/ijd.2019.98364
Namazi MR, Shotorbani AK (2015) Evaluation of the efficacy of topical ethyl vanillate in enhancing the effect of narrow band ultraviolet b against vitiligo: a double blind randomized, placebo-controlled clinical trial. Iran J Med Sci 40(6):478–484. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628137/pdf/IJMS-40-478.pdf
Nguyen S, Chuah SY, Fontas E et al (2018) Atorvastatin in combination with narrowband uv-b in adult patients with active vitiligo: a randomized clinical trial. JAMA Dermatol 154(6):725–726. https://doi.org/10.1001/jamadermatol.2017.6401
doi: 10.1001/jamadermatol.2017.6401
pubmed: 29617528
pmcid: 6583848
Omidian M, Asadian T (2018) Evaluation of serum vitamin d levels in patients with vitiligo undergoing nbuvb (narrowband uv-b) therapy. Jundishapur J Nat Pharm Prod 13(2):e65045. https://doi.org/10.5812/jjnpp.65045
doi: 10.5812/jjnpp.65045
Omidian M, Pazyar N, Zahra-al Sadat M (2018) Is vitamin d supplement accompanied with narrow band uvb effective for treatment of vitiligo? Comp Clin Pathol 27(3):685–690. https://doi.org/10.1007/s00580-018-2651-3
doi: 10.1007/s00580-018-2651-3
Panigrahi H, Rana R, Rao MM (2012) Efficacy of leech therapy and ayurvedic compound in vitiligo: a quasi experimental study. Int J Res Ayur Pharm 3:868–871. https://doi.org/10.7897/2277-4343.03640
doi: 10.7897/2277-4343.03640
Patel HK, Barot BS, Parejiya PB, Shelat PK, Shukla A (2014) Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo–part ii: rheological characterization and in vivo assessment through dermatopharmacokinetic and pilot clinical studies. Colloids Surf B Biointerfaces 119:145–153. https://doi.org/10.1016/j.colsurfb.2014.02.005
doi: 10.1016/j.colsurfb.2014.02.005
pubmed: 24767976
Peralta-Pedrero ML, Morales-Sánchez MA, Jurado-Santa Cruz F, De la Torre-García ME, Cruz-Peralta ES, Olguín-García MG (2019) Systematic review of clinimetric instruments to determine the severity of non-segmental vitiligo. Australas J Dermatol 60(3):e178–e185. https://doi.org/10.1111/ajd.13008
doi: 10.1111/ajd.13008
pubmed: 30820942
Poolsuwan P, Churee C, Pattamadilok B (2020) Comparative efficacy between localized 308-nm excimer light and targeted 311-nm narrowband ultraviolet b phototherapy in vitiligo: a randomized, single-blind comparison study. Photodermatol Photoimmunol Photomed. https://doi.org/10.1111/phpp.12619
doi: 10.1111/phpp.12619
pubmed: 33047405
Rosmarin D, Pandya AG, Lebwohl M et al (2020) Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial. Lancet 396(10244):110–120. https://doi.org/10.1016/s0140-6736(20)30609-7
doi: 10.1016/s0140-6736(20)30609-7
pubmed: 32653055
Rothstein B, Joshipura D, Saraiya A et al (2017) Treatment of vitiligo with the topical janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 76(6):1054-1060.e1051. https://doi.org/10.1016/j.jaad.2017.02.049
doi: 10.1016/j.jaad.2017.02.049
pubmed: 28390737
Sehrawat M, Arora TC, Chauhan A, Kar HK, Poonia A, Jairath V (2014) Correlation of vitamin d levels with pigmentation in vitiligo patients treated with nbuvb therapy. ISRN Dermatol 2014:493213. https://doi.org/10.1155/2014/493213
doi: 10.1155/2014/493213
pubmed: 25006488
pmcid: 4005019
Silpa-Archa N, Griffith JL, Williams MS, Lim HW, Hamzavi IH (2016) Prospective comparison of recipient-site preparation with fractional carbon dioxide laser vs. dermabrasion and recipient-site dressing composition in melanocyte-keratinocyte transplantation procedure in vitiligo: a preliminary study. Br J Dermatol 174(4):895–897. https://doi.org/10.1111/bjd.14204
doi: 10.1111/bjd.14204
pubmed: 26409069
Silpa-Archa N, Griffith JL, Huggins RH et al (2017) Long-term follow-up of patients undergoing autologous noncultured melanocyte-keratinocyte transplantation for vitiligo and other leukodermas. J Am Acad Dermatol 77(2):318–327. https://doi.org/10.1016/j.jaad.2017.01.056
doi: 10.1016/j.jaad.2017.01.056
pubmed: 28502377
Silpa-Archa N, Weerasubpong P, Junsuwan N, Yothachai P, Supapueng O, Wongpraparut C (2019) Treatment outcome and persistence of repigmentation from narrow-band ultraviolet b phototherapy in vitiligo. J Dermatolog Treat 30(7):691–696. https://doi.org/10.1080/09546634.2018.1544409
doi: 10.1080/09546634.2018.1544409
pubmed: 30474443
Singh A, Kanwar AJ, Parsad D, Mahajan R (2014) Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J Dermatol Venereol Leprol 80(1):29–35. https://doi.org/10.4103/0378-6323.125479
doi: 10.4103/0378-6323.125479
pubmed: 24448120
Szczurko O, Shear N, Taddio A, Boon H (2011) Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 11:21. https://doi.org/10.1186/1472-6882-11-21
doi: 10.1186/1472-6882-11-21
pubmed: 21406109
pmcid: 3065445
Taneja A, Kumari A, Vyas K, Khare AK, Gupta LK, Mittal AK (2019) Cyclosporine in treatment of progressive vitiligo: an open-label, single-arm interventional study. Indian J Dermatol Venereol Leprol 85(5):528–531. https://doi.org/10.4103/ijdvl.IJDVL_656_18
doi: 10.4103/ijdvl.IJDVL_656_18
pubmed: 31389371
Tawfik YM, Abd Elazim NE, Abdel-Motaleb AA, Mohammed RAA, Tohamy AMA (2019) The effect of nb-uvb on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios. J Cosmet Dermatol 18(2):638–646. https://doi.org/10.1111/jocd.12759
doi: 10.1111/jocd.12759
pubmed: 30280485
Thu HDT, Hong NDT, Van TN et al (2019) The decline of puva therapy in vietnam: effective treatment of narrow band uvb in vietnamese vitiligo patients. Open Access Maced J Med Sci 7(2):256–258. https://doi.org/10.3889/oamjms.2019.068
doi: 10.3889/oamjms.2019.068
pubmed: 30745974
pmcid: 6364711
Vanderweil SG, Amano S, Ko WC et al (2017) A double-blind, placebo-controlled, phase-ii clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol 76(1):150-151.e153. https://doi.org/10.1016/j.jaad.2016.06.015
doi: 10.1016/j.jaad.2016.06.015
pubmed: 27986135
pmcid: 5176345
Vinodini RAHA, Meenakshi Sundaram M, Muthukumar NJ (2019) Clinical evaluation of parangipattai chooranam (internal) and annabedhi chenduram (external) for venpulli (vitiligo) in children. Res J Pharm Technol 12(12):5932–5936. https://doi.org/10.5958/0974-360X.2019.01029.1
doi: 10.5958/0974-360X.2019.01029.1
Vu M, Heyes C, Robertson SJ, Varigos GA, Ross G (2017) Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol 42(8):942–944. https://doi.org/10.1111/ced.13290
doi: 10.1111/ced.13290
pubmed: 29034491
Zabolinejad N, Maleki M, Salehi M, Ashrafi Z, Molkara S, Layegh P (2020) Psoralen and narrowband uvb combination provides higher efficacy in treating vitiligo compared with narrowband uvb alone: a randomised clinical trial. Australas J Dermatol 61(1):e65–e69. https://doi.org/10.1111/ajd.13184
doi: 10.1111/ajd.13184
pubmed: 31651037
Zahoor M, Shaukat S, Khan MS, Ahmad TJ (2017) Comparison of efficacy and safety of 0.005% calcipotriol ointment versus 0.05% betamethasone dipropionate ointment versus calcipotriol plus betamethasone ointment for the treatment of vitiligo. J Pak Assoc Dermatol 27(1):30–36
Zhang L, Wang X, Chen S et al (2019) Comparison of efficacy and safety profile for home nb-uvb vs. Outpatient nb-uvb in the treatment of non-segmental vitiligo: a prospective cohort study. Photodermatol Photoimmunol Photomed 35(4):261–267. https://doi.org/10.1111/phpp.12462
doi: 10.1111/phpp.12462
pubmed: 30854736